These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27543192)

  • 21. Cystic acne due to imatinib therapy for chronic myelocytic leukemia.
    Hwang A; Iskandar A; Del Rosario M; Dasanu CA
    J Oncol Pharm Pract; 2019 Jun; 25(4):972-974. PubMed ID: 29498323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.
    Harding DJ; MacQuillan G; Howman R; de Boer B; Adams L; Mitchell A; Jeffrey G
    J Clin Oncol; 2016 Apr; 34(11):e97-8. PubMed ID: 25267743
    [No Abstract]   [Full Text] [Related]  

  • 23. Imatinib is still recommended for frontline therapy for CML.
    Hantel A; Larson RA
    Blood Adv; 2018 Dec; 2(24):3648-3652. PubMed ID: 30587493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?
    Eskazan AE; Tiribelli M
    Leuk Res; 2018 Nov; 74():55-56. PubMed ID: 30296661
    [No Abstract]   [Full Text] [Related]  

  • 25. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment.
    Angriman F; Gutierrez Acevedo MN; Rossi MS; Gimenez Conca AD; Otero V; Arbelbide JA; Michelángelo H
    Turk J Haematol; 2015 Jun; 32(2):193-4. PubMed ID: 26316496
    [No Abstract]   [Full Text] [Related]  

  • 27. A case report of rare palmoplantar keratosis and nail dystrophy with imatinib.
    Benabbes M; Tazi Mezalek Z; Meddah B
    Ann Pharm Fr; 2017 May; 75(3):172-175. PubMed ID: 28189257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
    Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
    Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What Happens When Imatinib Goes Generic?
    McDougall J; Ramsey SD; Radich J
    J Natl Compr Canc Netw; 2016 Feb; 14(2):128-31. PubMed ID: 26850483
    [No Abstract]   [Full Text] [Related]  

  • 30. The Importance of Being Cured: A Chronic Myeloid Leukemia Perspective.
    Raanani P
    Acta Haematol; 2016; 135(3):131-2. PubMed ID: 26535978
    [No Abstract]   [Full Text] [Related]  

  • 31. Imatinib-Associated Pneumocystis jirovecii Pneumonia in a Patient With Chronic Myeloid Leukemia.
    Daw J; Thapa B; Chahine J; Lak H; Perez O; Nair R; Alomari M; Haddad A
    Am J Ther; 2020; 27(4):e406-e409. PubMed ID: 31356343
    [No Abstract]   [Full Text] [Related]  

  • 32. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
    Lee SE; Choi SY; Song HY; Kim SH; Choi MY; Park JS; Kim HJ; Kim SH; Zang DY; Oh S; Kim H; Do YR; Kwak JY; Kim JA; Kim DY; Mun YC; Lee WS; Chang MH; Park J; Kwon JH; Kim DW
    Haematologica; 2016 Jun; 101(6):717-23. PubMed ID: 26888022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia.
    Yamaguchi J; Fujino T; Isa R; Nishiyama D; Kuwahara-Ota S; Kawaji Y; Tsukamoto T; Chinen Y; Shimura Y; Kobayashi T; Horiike S; Kohno K; Nakamura S; Kuroda J
    Haematologica; 2019 Aug; 104(8):e376-e379. PubMed ID: 30975907
    [No Abstract]   [Full Text] [Related]  

  • 34. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
    Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
    J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The biology of CML supports second-generation TKIs as frontline treatment.
    Fava C; Saglio G
    Clin Adv Hematol Oncol; 2017 Apr; 15(4):302-307. PubMed ID: 28591106
    [No Abstract]   [Full Text] [Related]  

  • 36. Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
    Singh S; Sharma PK
    Indian J Pharmacol; 2016; 48(4):458-459. PubMed ID: 27756963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Abnormal nails].
    Nassarmadji K; Marie I
    Rev Med Interne; 2018 Jun; 39(6):443-444. PubMed ID: 27789028
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Stagno F; Iurlo A; Albano F; Abruzzese E; Martino B; Levato L; Intermesoli T; Pregno P; Rossi G; Gherlinzoni F; Leoni P; Cavazzini F; Venturi C; Soverini S; Testoni N; Alimena G; Cavo M; Martinelli G; Pane F; Saglio G; Rosti G; Baccarani M;
    Leukemia; 2015 Sep; 29(9):1823-31. PubMed ID: 26088952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
    Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
    Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
    [No Abstract]   [Full Text] [Related]  

  • 40. Analyses of Treatment Outcome According to Age in Patients With Chronic Myeloid Leukemia Receiving Front-line Imatinib Therapy.
    Ćojbašić I; Mačukanović-Golubović L; Vučić M; Tijanić I
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):696-702. PubMed ID: 28712742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.